Product Reports Resources Pricing Login Book a demo
COMPANY PROFILE

Cairn Therapeutics

Request full access

Aiding in the fight against cancer through the development of a prodrug, CT 262, which selectively targets and inhibits tumor growth while sparing healthy cells

Wilmington, United StatesFounded 2016Biotech & Life Sciences

About Cairn Therapeutics

Cairn Therapeutics is focused on developing advanced cancer treatments, specifically through its innovative compound CT 262. This prodrug is selectively activated within cancer cells, targeting DNA to induce programmed cell death while sparing healthy cells. The company operates in the oncology market, serving patients and healthcare providers seeking effective cancer therapies. Cairn Therapeutics' business model revolves around the research, development, and eventual commercialization of its proprietary compounds. Revenue is generated through partnerships, licensing agreements, and future sales of its therapeutic products. CT 262 has shown promising results in preclinical studies, demonstrating high efficacy and a broad therapeutic window. The company aims to provide a significant advancement in cancer treatment, offering a solution that inhibits tumor growth in a dose-dependent manner and continues its effects even after the last dose.

Source: Dealroom company data

At a glance

Status
Operational
Founded
2016
Headquarters
Wilmington, United States
Employees
4
Open positions
None listed
Dealroom signal
26.3/100
Industry
Health
Sub-industry
BioTechnology
Sector
Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model
Manufacturing
Client focus
B2B

Funding history

4 recorded events

Company financing events and reported valuations.

Deal typeDateAmountValuationInvestorsSource
SERIES A✓Equity / VC Oct 2024 $15M $60M Undisclosed ↗
EARLY VC✓Equity / VC Oct 2024 $4M $16M Undisclosed ↗
Showing the latest 2 of 4 recorded eventsBook a demo for the full funding history →

Growth signals

Cairn Therapeutics website traffic

Latest recorded traffic for Cairn Therapeutics is 980 monthly website visits, up 2.1% over the last three months. Cairn Therapeutics's team grew 0% over the past year.

Latest monthly visits980 3-month web change+2.1% 1-year team growth0%
Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Showing 8 of the closest matchesCompare every metric →

Investments and acquisitions

Capital deployed

Recent portfolio relationships for companies that also act as investors or acquirers.

Cairn Therapeutics in the Wilmington ecosystem

Live from Dealroom

The Cairn Therapeutics office with the hot startups, most funded companies and investors around it. Hover or tap a pin.

Loading the map…

Dealroom maps whole ecosystems like this one for cities, regions and governments. See the ecosystem platform →

Investors

1 investor on the cap table

From Dealroom's funding and investor records, grouped by the round each investor first entered.

Other known investors1 additional known investor

  • Scripps Translational Science Institute
Team profiled 1 named & role-tagged
Founders Hidden — book a demo/100 quality score
Key operators Hidden — book a demo quality score
Potential founders Hidden — book a demo likely future founders
Startup mafia Hidden — book a demo alumni-founded startups
Talent movements Hidden — book a demo in · Hidden — book a demo out past 12 months

Source: Dealroom Talent Intelligence.

Global footprint

Workforce and web traffic by country
Workforce by country
1 countries with
team presence
🇺🇸 United States100%
1 country shown

Market sentiment

Posts on X, past 7 days

An AI-synthesised read of the highest-engagement posts about Cairn Therapeutics on X, ranked by likes and reposts, corporate channels excluded.

Reading the room on X — pulling top posts and synthesizing themes…

Source: X recent search ranked by engagement (likes + retweets) · Synthesis by Claude · Cached for 1 hour

See Cairn Therapeutics’s full profile on Dealroom

Request a free trial to see the complete deal history, financials, people graph and growth signals.

Takes under a minute. Already use Dealroom? Log in.